Secretion of the Toxin ExoU Is a Marker for Highly Virulent Pseudomonas aeruginosa Isolates Obtained from Patients with Hospital-Acquired Pneumonia

Journal of Infectious Diseases

Volumn 188, Issue 11, 2003, Pages 1695-1706

  Schulert, Grant S ^a,c   Feltman, Heather ^a,d   Rabin, Shira D P ^a   Martin, Ciara G ^a   Battle, Scott E ^a   Rello, Jordi ^b   Hauser, Alan R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BIOLOGICAL MARKER; EXOS PROTEIN; EXOU PROTEIN; EXOY PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CELL DEATH; CELL SECRETION; CONTROLLED STUDY; CYTOLYSIS; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; MARKER GENE; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA;

ANIMALS; APOPTOSIS; BACTERIAL PROTEINS; CROSS INFECTION; GLUCOSYLTRANSFERASES; MICE; MICE, INBRED BALB C; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; VIRULENCE;

EID: 0346256754     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379372     Document Type: Article

References (78)

1. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153:1711-25.
2. Niederman MS. Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences. Semin Respir Infect 1990; 5: 173-84.
3. Dunn M, Wunderink RG. Ventilator-associated pneumonia caused by Pseudomonas infection. Clin Chest Med 1995; 16:95-109.
4. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160:608-13.
5. Fagon JY, Chastre J, Domart Y, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1989; 139:877-84.
6. George DL, Galk PS, Wunderink RG, et al. Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am J Respir Crit Care Med 1998; 158:1839-47.
7. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes. Chest 1998; 113:412-20.
8. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance report, data summary from October 1986-April 1996, issued May 1996. Am J Infect Control 1996; 24:380-8.
9. Rello I, Rue M, Jubert P, et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25:1862-7.
10. Rello I, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104:1230-5.
11. Rello J, Jubert P, Valles J, Artigas A, Rue M, Niederman MS. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 1996; 23:973-8.
12. Kollef M, Silver P, Murphy D, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995; 108:1655-62.
13. Brewer SC, Wunderink RG, Jones CB, Leeper KV. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996; 109:1019-29.
14. Fagon J-Y, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94:281-8.
15. Pennington JE. Nosocomial respiratory infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2599-607.
16. Frank D. The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol 1997; 26:621-9.
17. Knight DA, Finck-Barbancon V, Kulich SM, Barbieri JT. Functional domains of Pseudomonas aeruginosa exoenzyme S. Infect Immun 1995; 63:3182-6.
18. Frithz-Lindsten E, Du Y, Rosqvist R, Forsberg A. Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxidty and disruption of actin microfilaments. Mol Microbiol 1997; 25:1125-39.
19. Goehring U-M, Schmidt G, Pederson KJ, Aktories K, Barbieri JT. The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases. J Biol Chem 1999; 274:36369-72.
20. Krall R, Sun J, Pederson KJ, Barbieri JT. In vivo rho GTPase-activating protein activity of Pseudomonas aeruginosa cytotoxin ExoS. Infect Immun 2002; 70:360-7.
21. Pederson KJ, Vallis AJ, Aktories K, Frank DW, Barbieri JT. The amino-terminal domain of Pseudomonas aeruginosa ExoS disrupts actin filaments via small-molecular-weight GTP-binding proteins. Mol Microbiol 1999; 32:393-401.
22. Vallis AJ, Finck-Barbancon V, Yahr TL, Frank DW. Biological effects of Pseudomonas aeruginosa type III-secreted proteins on CHO cells. Infect Immun 1999; 67:2040-4.
23. Olson JC, Fraylick JE, McGuffie EM, et al. Interruption of multiple cellular processes in HT-29 epithelial cells by Pseudomonas aeruginosa exoenzyme S. Infect Immun 1999; 67:2847-54.
24. Olson JC, McGuffie EM, Frank DW. Effects of differential expression of the 49-kilodalton exoenzyme S by Pseudomonas aeruginosa on cultured eukaryotic cells. Infect Immun 1997; 65:248-56.
25. Pederson KJ, Barbieri JT. Intracellular expression of the ADP-ribosyltransferase domain of Pseudomonas aeruginosa exoenzyme S is cytotoxic to eukaryotic cells. Mol Microbiol 1998; 30:751-9.
26. Cowell BA, Chen DY, Frank DW, Vallis AJ, Fleiszig SMJ. Exo T of cytotoxic Pseudomonas aeruginosa prevents uptake by corneal epithelial cells. Infect Immun 2000; 68:403-6.
27. Fleiszig SMJ, Wiener-Kronish JP, Miyazaki H, et al. Pseudomonas aeruginoso-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect Immun 1997; 65:579-86.
28. Bruno TF, Woods DE, Mody CH. Exoenzyme S from Pseudomonas aeruginosa induces apoptosis in T lymphocytes. J Leukoc Biol 2000; 67:808-16.
29. Kaufman MR, Jia J, Zeng L, Ha U, Chow M, Jin S. Pseudomonas aeruginosa-mediated apoptosis requires the ADP-ribosylating activity of ExoS. Microbiology 2000; 146:2531-41.
30. Krall R, Schmidt G, Aktories K, Barbieri JT. Pseudomonas aeruginosa ExoT is a Rho GTPase-activating protein. Infect Immun 2000; 68:6066-8.
31. Kazmierczak BI, Engel JN. Pseudomonas aeruginosa ExoT acts in vivo as a GTPase-activating protein for RhoA, Rac1, and Cdc42. Infect Immun 2002; 70:2198-205.
32. Liu S, Yahr TL, Frank DW, Barbieri JT. Biochemical relationships between the 53-kilodalton (Exo53) and 49-kilodalton (ExoS) forms of exoenzyme S of Pseudomonas aeruginosa. J Bacteriol 1997; 179:1609-13.
33. Garrity-Ryan L, Kazmierczak B, Kowal R, Comolli J, Hauser A, Engel JN. The arginine finger domain of ExoT contributes to actin cytoskeleton disruption and inhibition of internalization of Pseudomonas aeruginosa by epithelial cells and macrophages. Infect Immun 2000; 68: 7100-13.
34. Geiser TK, Kazmierczak BI, Garrity-Ryan LK, Matthay MA, Engel JN. Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair. Cell Microbiol 2001; 3:223-36.
35. Coburn J, Frank D. Macrophages and epithelial cells respond differently to the Pseudomonas aeruginosa type III secretion system. Infect Immun 1999; 67:3151-4.
36. Finck-Barbancon V, Goranson J, Zhu L, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997; 25:547-57.
37. Hauser AR, Kang PJ, Engel J. PepA, a novel secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence. Mol Microbiol 1998; 27:807-18.
38. Hauser AR, Engel JN. Pseudomonas aeruginosa induces type III secretion-mediated apoptosis of macrophages and epithelial cells. Infect Immun 1999; 67:5530-7.
39. Finck-Barbancon V, Frank DW. Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU. J Bacteriol 2001; 183: 4330-44.
40. Yahr TL, Vallis AJ, Hancock MK, Barbieri JT, Frank DW. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Natl Acad Sci USA 1998; 95:13899-904.
41. 4L Kudoh I, Wiener-Kronish JP, Hashimoto S, Pittet J-F, Frank D. Exoproduct secretions of P. aeruginosa strains influence severity of alveolar epithelial injury. Am J Physiol 1994; 267(5 Pt 1):L551-6.
42. Wiener-Kronish JP, Sakuma T, Kudoh I, et al. Alveolar epithelial injury and pleural empyema in acute Pseudomonas aeruginosa pneumonia in anesthetized rabbits. J Appl Physiol 1993; 75:1661-9.
43. Hauser AR, Cobb E, Bodi M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30:521-8.
44. Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767-74.
45. Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001; 147:2659-69.
46. Rello J, Mariscal D, March F, et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med 1998; 157:912-6.
47. Liu PV. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. II. Effects of lecithinase and protease. J Infect Dis 1966; 116:112-6.
48. Bjorn MJ, Pavlovskis OR, Thompson MR, Iglewski BH. Production of exoenzyme S during Pseudomonas aeruginosa infection in burned mice. Infect Immun 1979; 24:837-42.
49. Yahr TL, Barbieri JT, Frank DW. Genetic relationship between the 53-and 49-kilodalton forms of exoenzyme S from Pseudomonas aeruginosa. J Bacteriol 1996; 178:1412-9.
50. Vogel HJ, Bonner DM. Acetylornithinase of Escherichia coli partial purification and some properties. J Biol Chem 1956; 218:97-106.
51. Simon R, Priefer U, Puhler A. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram negative bacteria. Biotechnology 1983; 1:784-91.
52. Schweizer HP, Hoang TT. An improved system for gene replacement and xylE fusion analysis in Pseudomonas aeruginosa. Gene 1995; 158: 15-22.
53. Frank D, Iglewski BH. Cloning and sequence analysis of a trans-regulatory locus required for Exoenzyme S synthesis in Pseudomonas aeruginosa. J Bacteriol 1991; 173:6460-8.
54. Hovey AK, Frank DW. Analyses of the DNA-binding and transcriptional activation properties of ExsA, the transcriptional activator of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 1995; 177: 4427-36.
55. Yahr T, Frank D. Transcriptional organization of the trans-regulatory locus which controls exoenzyme S synthesis in Pseudomonas aeruginosa. J Bacteriol 1994; 176:3832-8.
56. Hauser AR, Kang PJ, Fleiszig SJM, Mostov K, Engel J. Defects in type III secretion correlate with internalization of Pseudomonas aeruginosa by epithelial cells. Infect Immun 1998; 66:1413-20.
57. Campbell M, Mahenthiralingam E, Speert DP. Evaluation of random amplified polymorphic DNA typing of Pseudomonas aeruginosa. J Clin Microbiol 2000; 38:4614-5.
58. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996; 34:1129-35.
59. Kang PJ, Hauser AR, Apodaca G, et al. Identification of Pseudomonas aeruginosa genes required for epithelial cell injury. Mol Microbiol 1997; 24:1249-62.
60. Nicas TI, Iglewski BH. Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S. Infect Immun 1984; 45:470-4.
61. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
62. Sambrook I, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
63. Apodaca G, Bomsel M, Lindstedt R, et al. Characterization of Pseudomonas aerugmosa-induced MDCK cell injury: glycosylation defective host cells are resistant to bacterial killing. Infect Immun 1995; 63: 1541-51.
64. Comolli JC, Hauser AR, Waite L, Whitchurch CB, Mattick JS, Engel JN. Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect Immun 1999; 67:3625-30.
65. Reed L, Muench J. A simple method for estimating fifty percent endpoints. Am J Hyg 1938; 27:493-7.
66. Yahr T, Mende-Mueller LM, Friese MB, Frank DW. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 1997; 179:7165-8.
67. Sawa T, Ohara M, Kurahashi K, et al. In vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections. Infect Immun 1998; 66:3242-9.
68. Grassme H, Kirschnek S, Riethmueller J, et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000; 290:527-30.
69. Jendrossek V, Grassme H, Mueller I, Lang F, Gulbins E. Pseudomonas aeruginosa-induced apoptosis involves mitochondria and stress-activated protein kinases. Infect Immun 2001; 69:2675-83.
70. Rajan S, Cacalano G, Bryan R, et al. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells. Am J Respir Cell Mol Biol 2000; 23:304-12.
71. Fleiszig SMJ, Zaidi TS, Preston MJ, Grout M, Evans DJ, Pier GB. Relationship between cytotoxidty and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun 1996; 64: 2288-94.
72. Dacheux D, Toussaint B, Richard M, Brochier G, Croize J, Attree I. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infect Immun 2000; 68:2916-24.
73. Hirakata Y, Finlay BB, Simpson DA, Kohno S, Kamihira S, Speert DP. Penetration of clinical isolates of Pseudomonas aeruginosa through MDCK epithelial cell monolayers. J Infect Dis 2000; 181:765-9.
74. Allewelt M, Coleman FT, Grout M, Priebe GP, Pier GB. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 2000; 68:3998-4004.
75. Bonten MJ, Gaillard CA, van Tiel FH, Smeets HG, van der Geest S, Stobberingh EE. The stomach is not a source for colonization of the upper respiratory tract and pneumonia in ICU patients. Chest 1994; 105:878-84.
76. Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun 2001; 69:5908-10.
77. Sawa T, Yahr T, Ohara M, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999; 5:392-8.
78. Shime N, Sawa T, Fujimoto J, et al. Therapeutic administration of anti-PcrV F(ab′)(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 2001; 167:5880-6.